Updated Jul 16, 2026
Levine James E. has filed 1 SEC Form 4 filing across 1 company in the last 90 days — buying. Lifetime open-market purchases: $37K. Historical track record: 1/5 stars across 3 tracked purchases.
InsiderAlpha computes a forward-return-based score for every insider with enough Form 4 purchase history. The metrics below reflect realised performance after each tracked open-market purchase.
| InsiderAlpha rating | ★☆☆☆☆ (1/5) |
|---|---|
| Total purchases tracked | 3 |
| Purchases with forward-return data | 3 |
| 30-day win rate | 0% |
| 90-day win rate | 3333% |
| Avg 5-day return | -1076.23% |
| Avg 30-day return | -2475.05% |
| Avg 90-day return | -1313.10% |
| Best 30-day return | -1464.02% |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2024-12-18 | CRDF | Cardiff Oncology, Inc. | P — Open-market purchase | 2.4K | $5.00 | $12K |
| 2024-12-18 | CRDF | Cardiff Oncology, Inc. | P — Open-market purchase | 2.8K | $5.42 | $15K |
| 2024-12-18 | CRDF | Cardiff Oncology, Inc. | P — Open-market purchase | 2.6K | $3.83 | $10K |
Levine James E. is a corporate insider — currently tracked as Chief Financial Officer of KAZIA THERAPEUTICS LTD (KZIA). InsiderAlpha tracks every SEC Form 4 filing in real time.
1 primary Form 4 filings in the last 90 days, covering 1 company.
Recorded transactions: 3 open-market purchases ($37K) and 0 open-market sales () across all tracked filings.
Across 3 tracked purchases, Levine James E. averaged -2475.0% avg 30-day return with a 0% 30-day win rate. InsiderAlpha rates the track record at 1/5 stars.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Levine James E. profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.